To NASDAQ OMX Copenhagen A/S
Announcement No. 12-09 / Copenhagen, 20 April 2009
TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
Copenhagen, Denmark - 20 April 2009 - TopoTarget A/S (OMX: TOPO) announces
continued increased growth of 66% from DKK 7.0 million to DKK 11.6 million in
sales of Savene® and Totect® in Europe and the US in Q1 2008 compared with Q1
2009.
Sales of TopoTarget's first marketed product, Savene® and Totect®, continue to
rise. In 2008, we were close to doubling our sales from DKK 21.9 million to DKK
39.1 million relative to 2007.
Sales have continued to climb from DKK 3.7 million in Q1 2007 to DKK 7.0
million in Q1 2008 and now to DKK 11.6 million in Q1 2009. This is an increase
from Q1 2007 to Q1 2008 of 89%, from Q1 2008 to Q1 2009 of 66%. Since Q3 2008
sales of Savene® and Totect® have generated a profit for the product in the two
continents.
The sales figures show that more and more European and US doctors and nurses
are using the product.
TopoTarget estimates that the combined market in the US and Europe for
Savene®/Totect® represents DKK 40-50 Euro per year.
Savene®/Totect® is the only approved and evidence-based treatment of
anthracycline extravasation and has been recommended by oncology nurse
organisations on both sides of the Atlantic, a key factor for the product's
dissemination.
“It is highly satisfactory that sales of Savene®/Totect® continue to increase
and that we now have a net profit on the products and I'm very happy to see
that our products create value for cancer patients," says professor Peter Buhl
Jensen, CEO of TopoTarget.
For graphs over sales please see attached PDF.
TopoTarget A/S
For further information, please contact:
Peter Buhl Jensen Telephone +45 39 17 94 99
CEO Mobile +45 21 60 89 22
Background information
About Savene®/Totect®
Savene®/Totect® is a catalytic inhibitor of Topoisomerase II, an enzyme found
in the cell nucleus. Topoisomerase enzymes are essential for cell growth and
proliferation and the target for a group of anti-cancer chemotherapeutics
called anthracyclines. Savene®/Totect® blocks the activity of the topoisomerase
enzyme and prevents the effect of anthracyclines.
Savene®/Totect® is used as a detoxifying agent, administered intravenously as
an antidote following an extravasation. An extravasation is a serious clinical
accident in which anthracyclines accidentally leak into surrounding tissue. The
high concentration of drug causes severe and cumulative damage to the skin,
subcutaneous tissue, muscle and nerves. Current treatment often involves
surgical removal of the tissue followed by plastic surgery and rehabilitation.
The use of dexrazoxane (the active ingredient in Savene®/Totect®) to treat
anthracycline extravasation is protected by patent in several countries
including EU and the US. The US patent number is 6,727,253 B2.
